

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INTAS PHARMACEUTICALS LTD.,
Petitioner

v.

ATOSSA THERAPEUTICS, INC.,
Patent Owner

CASE: PGR2023-00043

Patent No. 11,572,334

PATENT OWNER'S UPDATED MANDATORY NOTICES

PURSUANT TO 37 C.F.R. § 42.8

Pursuant to 37 C.F.R. § 42.8, Patent Owner Atossa Therapeutics, Inc. hereby submits the following mandatory notices in response to the Petition for Post-Grant Review of U.S. Patent No. 11,572,334 (“the ’334 patent”).

A. Real Party-In-Interest (37 C.F.R. § 42.8(b)(1))

The patent owner and real party-in-interest is Atossa Therapeutics, Inc.

B. Related Matters Under 37 C.F.R. § 42.8(b)(2)

The ’334 patent is not involved in any related litigation matters.

The ’334 patent was filed as U.S. Patent Application No. 17/580,428. The ’334 patent claims the benefits of Provisional Application Nos. 62/693,885, filed Jul. 3, 2018; 62/624,787, filed Jan. 31, 2018; 62/556,884, filed Sept. 11, 2017; and 62/556,799, filed Sept. 11, 2017. The ’334 patent also claims the benefit of PCT/US2018/050272, filed Sept. 10, 2018; and U.S. Patent Application No. 16/641,985, filed Sept. 10, 2018 (now U.S. Patent No. 11,261,151). U.S. Patent Application Nos. 18/090,757 (now U.S. Patent No. 11,680,036) filed Dec. 29, 2022; and 18/128,536, filed Mar. 30, 2023, are continuations of the application leading to the ’334 patent.

C. Lead and Back-up Counsel Under 37 C.F.R. § 42.8(b)(3)

Lead Counsel	Back-Up Counsel
<p>Lisa A. Haile (Reg. No. 38347) Lisa.haile@us.dlapiper.com</p> <p><u>Postal and Hand-Delivery Address:</u> DLA Piper LLP (US) 4625 Executive Drive, Suite 1100 San Diego, CA 92121-2133 Telephone: (858) 677-1400 Facsimile: (858) 677-1401</p>	<p>Susan M. Krumplitsch (<i>pro hac vice</i> granted, Paper 9) Susan.Krumplitsch@us.dlapiper.com</p> <p><u>Postal and Hand-Delivery Address:</u> DLA Piper LLP (US) 701 Fifth Avenue Suite 6900 Seattle, WA 98104-7044 Telephone: (206) 839-4815 Facsimile: (206) 299-4205</p>

D. Service Information Under 37 C.F.R. § 42.8(b)(4)

Service information for lead and back-up counsel is provided in the designation of lead and back-up counsel above. Service of any documents via hand delivery may be made at the postal mailing address of the respective lead and backup counsel designated above. Patent Owner hereby consents to electronic service by email at Lisa.Haile@us.dlapiper.com, Susan.Krumplitsch@us.dlapiper.com, and SeattlePTABDocket@us.dlapiper.com.

Dated: January 8, 2025

Respectfully Submitted,

/Susan M. Krumplitsch/
Susan M. Krumplitsch, admitted *pro hac vice*
DLA Piper LLP (US)
701 Fifth Avenue

Patent Owner's Updated Mandatory Notices

PGR2023-00043

U.S. Patent No. 11,572,334

Suite 6900

Seattle, WA 98104-7044

Attorney for Patent Owner

CERTIFICATE OF SERVICE

The undersigned hereby certifies that on this 8th day of January 2025, a true copy of the foregoing was served on Petitioner INTAS PHARMACEUTICALS LTD. by emailing a copy to counsel of record for Petitioner at the email addresses listed below:

Alejandro Menchaca
amenchaca@mcandrews-ip.com

Ben J. Mahon
bmahon@mcandrews-ip.com

334PGR@mcandrews-ip.com

Dated: January 8, 2025

/ Susan M. Krumplitsch /
Susan M. Krumplitsch, admitted *pro hac vice*
DLA Piper LLP (US)
701 Fifth Avenue
Suite 6900
Seattle, WA 98104-7044
Attorney for Patent Owner